• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

CRISPR screens identify novel targets that sensitize prostate cancer cells to ionizing radiation.

Research Project

Project/Area Number 20K18090
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 56030:Urology-related
Research InstitutionOsaka University

Principal Investigator

Hatano Koji  大阪大学, 医学系研究科, 講師 (60762234)

Project Period (FY) 2020-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2021: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2020: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Keywords前立腺癌 / 放射線治療 / CRISPR/Cas9 / CRISPR / スクリーニング / 放射線
Outline of Research at the Start

放射線治療は前立腺癌に対する有効な治療法であり、近年骨転移を来した去勢抵抗性前立腺癌に対するRI内用療法が注目されている。しかし、RI内用療法単独の治療効果は限定的で治療後の再発が問題となる。本研究では放射線増感ターゲット遺伝子を前立腺癌特異的に抑制することで、正常組織への副作用を軽減しつつ癌への放射線治療効果を高める新規治療法の開発を目的とする。CRISPRスクリーニングを用いて放射線増感ターゲット遺伝子の探索を行い、標的遺伝子を同定する。さらに、前立腺癌を標的としたsiRNAデリバリー技術との融合を行い、画期的新薬(ファースト・イン・クラス)の開発を目指す。

Outline of Final Research Achievements

Recently, cancer genomics has become important in the selection of treatment for prostate cancer. We performed a comprehensive knockout screen using the CRISPR/cas9 system in prostate cancer cell lines to identify radiosensitizing target genes. We identified top-ranked candidate genes that commonly exhibit radiosensitizing effects in the prostate cancer cell lines (PC3, 22RV1, and LNCaP). By the colony formation assay, the radiosensitization efficacy was confirmed using prostate cancer cells in which radiosensitization target genes are knocked out. The DNA repair after radiation therapy was delayed in the knock-out cells which was confirmed by the γH2AX assay and the Comet assay. Radiosensitivity was restored by knock-in of radiosensitizing target genes into the knock-out cell lines. We are planning additional experiment using mouse model in order to aim for therapeutic application to prostate cancer.

Academic Significance and Societal Importance of the Research Achievements

前立腺癌の治療においてがんゲノムの重要性が高まっている。放射線治療は前立腺癌に対する有効な治療法であり、近年骨転移を来した去勢抵抗性前立腺癌に対するRI内用療法が注目されている。しかし、RI内用療法単独の治療効果は限定的で治療後の再発が問題となる。放射線治療に影響を及ぼすがんゲノムの研究は、治療選択や新たな治療法の確立のためにも意義深い。本研究において、申請者らは放射線治療の感受性に影響を与えるターゲット遺伝子を同定した。この放射線増感ターゲット遺伝子を前立腺癌特異的に抑制することで、正常組織への副作用を軽減しつつ癌への放射線治療効果を高める新規治療法の開発が期待される。

Report

(3 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • Research Products

    (6 results)

All 2023 2021 2020

All Journal Article (4 results) (of which Peer Reviewed: 4 results,  Open Access: 3 results) Presentation (2 results)

  • [Journal Article] Extracellular vesicles in prostate cancer: a narrative review2021

    • Author(s)
      Hatano K, Fujita K
    • Journal Title

      Transl Androl Urol

      Volume: - Issue: 4 Pages: 1890-1907

    • DOI

      10.21037/tau-20-1210

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration-resistant prostate cancer.2020

    • Author(s)
      Fujita K, Kato T, Hatano K, Kawashima A, Ujike T, Uemura M, Imamura R, Okihara K, Ukimura O, Miki T, Nakajima T, Kaneda Y, Nonomura N.,
    • Journal Title

      Cancer Sci.

      Volume: in press Issue: 5 Pages: 1692-1698

    • DOI

      10.1111/cas.14366

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Application of Anti-Inflammatory Agents in Prostate Cancer.2020

    • Author(s)
      Hatano K, Fujita K, Nonomura N.
    • Journal Title

      J Clin Med.

      Volume: 9 Issue: 8 Pages: 2680-2706

    • DOI

      10.3390/jcm9082680

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Stereotactic Body Radiotherapy Using CyberKnife for Localized Low- and Intermediate-risk Prostate Cancer: Initial Report on a Phase I/II Trial2020

    • Author(s)
      Nakamura R, Hirata T, Suzuki O, Otani K, Kai N, Hatano K, Fujita K, Uemura M, Imamura R, Tanaka K, Yoshioka Y, Nonomura N, Ogawa K.
    • Journal Title

      Anticancer Res.

      Volume: 40 Issue: 4 Pages: 2053-2057

    • DOI

      10.21873/anticanres.14162

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] CRISPRスクリーニングによる放射線増感ターゲットの探索と前立腺癌への治療応用2023

    • Author(s)
      波多野 浩士
    • Organizer
      第110回日本泌尿器科学会総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 臨床的意義のある前立腺癌の診断における再生検時の前立腺multiparametric MRIの有用性2020

    • Author(s)
      波多野浩士, 河嶋厚成, 加藤大悟, 氏家 剛, 藤田和利, 植村元秀, 野々村祝夫
    • Organizer
      第108回日本泌尿器科学会総会
    • Related Report
      2020 Research-status Report

URL: 

Published: 2020-04-28   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi